Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the impact on cellular and cognitive functions affected by Aβ has not been tested. We used a controllable APP transgenic mouse model to test whether combining genetic suppression of Aβ production with passive anti-Aβ immunization improved functional outcomes over either treatment alone. Compared with behavior before treatment, arresting further Aβ production (but not passive immunization) was sufficient to stop further decline in spatial learning, working memory, and associative memory, whereas combination treatment reversed each of these impairments. Cognitive improvement coincided with resolution of neuritic dystrophy, restoration of synaptic density surrounding deposits, and reduction of hyperactive mammalian target of rapamycin signaling. Computational modeling corroborated by in vivo microdialysis pointed to the reduction of soluble/exchangeable Aβ as the primary driver of cognitive recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
The contextual brain: implications for fear conditioning, extinction and psychopathology
Maren, S., Phan, K. L., & Liberzon, I. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3492 · Cited by 1,547 · cited 1×
“This discrepancy may be explained by greater reliance on brain areas such as the amygdala in FC that were not tested for Aβ (Maren et al., 2013; Herry and Johansen, 2014) or may indicate that performance in this task is not dependent on Aβ load.”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Second, once free antibody encounters Aβ, the resulting antigen–antibody complex is quite stable, essentially rendering the bound antibody inactive (DeMattos et al., 2001; Levites et al., 2006b).”
BackgroundLacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 1×
“…markers in the plaque boundary area Exposure to soluble oligomeric Aβ can induce reversible spine loss in hippocampal neurons (Calabrese et al., 2007; Lacor et al., 2007; Shankar et al., 2007), and we were curious to test whether synaptic markers would recover with oligomer reduction in vivo.”
BackgroundReversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882 · cited 1×
“…learning and contextual discrimination while lowering the threshold for synaptic potentiation; in turn, pharmacologic intervention with rapamycin rescued cognitive behavior and synaptic sensitivity, suggesting that mTOR hyperactivity was also necessary for these phenotypes (Ehninger et al., 2008).”
BackgroundMolecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 2×
“…confirmed prior work suggesting that the small amount of mobile Aβ in soluble form has a disproportionate influence on cognitive performance compared with the much larger concentration of Aβ held in fibrillar plaques (Dodart et al., 2002; Zhang et al., 2011; Fowler et al., 2014; Liu et al., 2015).”
BackgroundResultKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561 · cited 1×
“Dystrophic neurites are prominent in the immediate vicinity of fibrillar plaques, swollen with aggregated proteins and interrupted vesicles that interfere with electrical transmission and cargo trafficking (Knowles et al., 1999; Stern et al., 2004; Tsai et al., 2004; Stokin et al., 2005).”
BackgroundEncoding of fear learning and memory in distributed neuronal circuits
Herry, C., & Johansen, J. P. (2014) · Nature Neuroscience · doi:10.1038/nn.3869 · Cited by 474 · cited 1×
“This discrepancy may be explained by greater reliance on brain areas such as the amygdala in FC that were not tested for Aβ (Maren et al., 2013; Herry and Johansen, 2014) or may indicate that performance in this task is not dependent on Aβ load.”
BackgroundGriffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459 · cited 2×
“mTOR hyperactivity has been detected in human AD brains and APP transgenic mice and can be induced by Aβ in wild-type mice (An et al., 2003; Griffin et al., 2005; Caccamo et al., 2010, 2011).”
BackgroundCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Self-citationCaccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362
An, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312 · cited 2×
“mTOR hyperactivity has been detected in human AD brains and APP transgenic mice and can be induced by Aβ in wild-type mice (An et al., 2003; Griffin et al., 2005; Caccamo et al., 2010, 2011).”
BackgroundmTORC2 controls actin polymerization required for consolidation of long-term memory
Huang, W., Zhu, P. J., Zhang, S., Zhou, H., Stoica, L., Galiano, M., Krnjević, K., Roman, G., & Costa-Mattioli, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3351 · Cited by 307
Alamed, J., Wilcock, D. M., Diamond, D. M., Gordon, M. N., & Morgan, D. (2006) · Nature Protocols · doi:10.1038/nprot.2006.275 · Cited by 256 · cited 1×
“We then reconfigured the pool to a six-arm radial maze as a 1-d test of working memory (modified from Alamed et al., 2006).”
MethodKnowles, R. B., Wyart, C., Buldyrev, S. V., Cruz, L., Urbanc, B., Hasselmo, M. E., Stanley, H. E., & Hyman, B. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5274 · Cited by 241
Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020355 · Cited by 237
Self-citationHartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0664-05.2005 · Cited by 147 · cited 1×
“…been overcome by increasing the dose of Ab9; however, at 500 µg/wk, the mice were already at the limit of what has been used in past animal studies (Hartman et al., 2005; Levites et al., 2006a) and equivalent to high-dose anti-Aβ antibody in current human clinical trials (i.e., 1,200 mg…”
MethodIn vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
Ulrich, J. D., Burchett, J. M., Restivo, J. L., Schuler, D. R., Verghese, P. B., Mahan, T. E., Landreth, G. E., Castellano, J. M., Jiang, H., Cirrito, J. R., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-13 · Cited by 128
Self-citationWang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · cited 4×
“Using this controllable APP model, we have previously shown that transgene suppression alone halts further amyloid formation but, when combined with passive anti-Aβ immunization, results in the clearance of up to 50% of deposited Aβ from the brain (Wang et al., 2011).”
BackgroundResultInfluentialSelf-citationInsights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116 · cited 5×
“Although dox-mediated control of transgenic APP was used to lower Aβ production, passive anti-Aβ immunization with mouse monoclonal IgG2a antibody Ab9 was used to sequester Aβ after its release (Levites et al., 2006a).”
BackgroundMethodInfluentialSelf-citationRoscic, A., Baldo, B., Crochemore, C., Marcellin, D., & Paganetti, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07435.x · Cited by 92 · cited 2×
“Consistent with this role, hyperactive mTOR signaling was shown to cause autophagic arrest in models of AD and other proteinopathies where genetic or pharmacologic mTOR suppression restored autophagic flux and promoted degradation of intraneuronal aggregates (Berger et al., 2006; Crews et al., 2010; Roscic et al., 201…”
BackgroundDi Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89 · cited 1×
“…of mTOR or its downstream targets—or pharmacologic intervention with rapamycin— attenuated synaptotoxicity, restored synaptic protein markers, and rescued cognitive impairment pointing toward a causal role in these features of disease (Oddo, 2012; Talboom et al., 2015; Di Domenico et al., 2018).”
BackgroundQuantitative and Mechanistic Studies of Aβ Immunotherapy
Golde, T., Das, P., & Levites, Y. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601830 · Cited by 46 · cited 1×
“The steadystate level of peripherally administered antibody within the CNS is estimated to be less than 0.1% of the total dose (Bard et al., 2000; Levites et al., 2006b; Golde et al., 2009).”
BackgroundInfluentialSelf-citationCharting a path toward combination therapy for Alzheimer’s disease
Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995168 · Cited by 37 · cited 1×
“Some in the field have responded to the limited success of this strategy by calling for combination treatments to be tested (Perry et al., 2015; Stephenson et al., 2015; Hendrix et al., 2016).”
Background
Cited by
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Meilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Metadata
- Authors
- Chiang, A. C. A., Fowler, S. W., Savjani, R. R., Hilsenbeck, S. G., Wallace, C. E., Cirrito, J. R., Das, P., & Jankowsky, J. L.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-04-06
- Volume
- 215
- Issue
- 5
- Pages
- 1349-1364
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2796268205
- Cited by
- 20
- References
- 27
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.